Form 4: Corbus Pharmaceuticals Director Rachelle Jacques Acquires Stock Options

Director Rachelle Suzanne Jacques acquired stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024.

Summary

• Rachelle Suzanne Jacques, a director of Corbus Pharmaceuticals Holdings, Inc., acquired stock options on May 16, 2024.
• The options, granting the right to buy 2,783 shares of common stock at $45.92, were awarded under the company's 2024 Equity Compensation Plan.
• The options vest 100% on the one-year anniversary of the grant date and expire on May 16, 2034.
• Following the transaction, Jacques directly owns 2,783 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard stock option grant to a director.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to improve company performance, benefiting shareholders.

Key Dates